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Abstract 
Purpose: To develop and characterize solid lipid nanoparticle (SLN) systems containing dextran sulfate 
or sodium alginate as anionic polymers for the delivery of clindamycin phosphate as a model hydrophilic 
cationic drug. 
Methods: A multi-level factorial design was used for the preparation and optimization of clindamycin 
SLNs. Polymers (dextran sulfate and sodium alginate), Tween 80, and Pluronic F68 were chosen as the 
independent variables. The SLNs were prepared using stearic acid as the lipid matrix by an emulsion 
congealing technique with cold homogenization. Particle size and drug loading were evaluated as the 
primary responses. The morphology and drug release rate of the selected formulations were also 
determined. 
Results: The results revealed that incorporation of anionic polymers increased drug loading of the 
SLNs. Dextran sulfate had a greater effect on drug loading, increasing it from 1.32 to  18.19 %, 
compared to the 6.73 % achieved using sodium alginate. Dextran sulfate also reduced drug release rate 
by half compared with sodium alginate, probably due to the higher charge density, lower molecular 
weight and lower branching density of the ionic polymer. 
Conclusion: Incorporation of anionic polymers can increase the loading of clindamycin phosphate into 
SLNs. Drug release from SLNs is also dependent on the polymer type.  
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Solid lipid nanoparticles (SLNs) consist of 
nanosized solid lipids dispersed in an aqueous 
medium. SLNs combine the advantages and 
avoid the disadvantages of other colloidal carrier 
systems such as liposomes and polymer 
nanoparticles, which are known as alternatives to 
SLNs [1-3]. SLN formulations are adhesive, and 
they could prolong the residence time of the 
dosage form at the absorption site, consequently 
increasing its bioavailability [4]. Controlled drug 
delivery, enhanced bioavailability of entrapped 
drugs [5], and/or improved tissue distribution, 
good tolerability, and drug targeting have been 
attributed to SLN formulations [6].  
 
Potential disadvantages such as an insufficient 
loading capacity, high initial burst release 
kinetics, drug leakage during storage, and 
relatively high water content of the dispersions 
(70–99.9%) have been observed [7,8]. 
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SLNs are usually applicable for entrapping 
lipophilic drugs [9,10]. However, for loading 
highly water-soluble, ionic drugs such as 
clindamycin, SLN formulations face the challenge 
of low drug partitioning in the lipid phase [11]. To 
deliver hydrophilic drugs, anionic polymers have 
been used to pair with cationic charged drugs to 
develop a polymer-lipid hybrid nanoparticle 
system, a variation of SLNs [12].  
 
Clindamycin is a semi-synthetic antibiotic with a 
wide spectrum of activity used in the treatment of 
certain types of bacterial infections, including 
those of the lungs, skin, blood, female 
reproductive organs and eye. In this study, we 
used ion-pairing method for the preparation of 
SLNs to decrease the hydrophilicity of 
clindamycin phosphate as a model hydrophilic 
cationic drug via the application of anionic 
polymers (dextran sulfate or sodium alginate). 
The effect of type and amount of polymers, 
amount of drug and surfactants on particle size, 
drug loading and drug release from SLNs were 
studied. Furthermore, the characteristics of 







Clindamycin phosphate was purchased from 
Behvazan Pharmaceutical Company, Iran. 
Sodium alginate and dextran sulfate were 
obtained from Applichem, Germany. Tween 80 
and stearic acid were purchased from Merck, 
Germany. Pluronic F68 was obtained from 
BASF, Germany. Acetonitrile was supplied by 





SLNs were prepared using a multi-level factorial 
design. Three independent variables including 
the amount of polymer (three levels), the amount 
of drug (two levels), and the amount of 
surfactants (two levels) were used (Table 1). The 
same amount of stearic acid was used in all 
formulations. The dependent variable or 
response was the drug loading. SPSS 16 
software was employed for the experimental 
design and regression analysis of the data to 
evaluate the effect of the variables on the 
responses.  
 
Preparation of clindamycin-loaded SLNs 
 
SLNs were prepared using an emulsion 
congealing technique with cold high-pressure 
homogenization. The oil and aqueous phases 
were prepared separately. The oil phase 
consisted of stearic acid (100 mg) and half of the 
total amount of the surfactant and co-surfactant 
used in the formulation (20 or 40 mg Tween 80 
and Pluronic F68, based on the experimental 
design) , while the aqueous phase consisted of 1 
mL double-distilled water, the drug (clindamycin 
phosphate, 2 or 4 mg), the other half of the 
surfactant and co-surfactant, and the anionic 
polymer (2 or 4 mg dextran sulfate or sodium 
alginate). The two phases were heated 
separately to 75 °C (almost 5°C higher than the 
melting point of stearic acid) for 10 min. The 
aqueous phase was added to the oil phase and 
mixed using a magnetic stirrer at the same 
temperature for 30 min. Afterward, the mixture 
was further treated by sonication (90 W) for 15 
min at 75 °C. The emulsion was poured into cold 
water (2 – 4 °C) to a final volume of 25 ml [10], 
and then the suspension was passed through a 
homogenizer (Emulsiflex-c3, Avestin, Canada) 
for five cycles (30 s for each cycle) at 20,000 
bars. 
 
Table 1: Independent variables (factors and levels for 
factorial design) 
        
  Levels   Independent variable   
−1 0 1 
X1: Amount of polymer (mg) 0 2 4 
X2: Amount of drug (mg) 2 - 4 
X3: Amount of surfactants (mg) 40 - 80 
    
Particle size determination 
 
The mean particle size and polydispersity index 
(PDI) of the SLNs were measured by photon 
correlation spectroscopy (PCS) (Scatteroscope 
1, Qudix, Seoul, Korea) using a helium-neon 
laser with a wavelength of 633 nm. Photon 
correlations of the spectroscopic measurements 
were determined at a scattering of 90°. A 1:100 
dilution of the formulation was made using 
double-distilled water before the measurement. 
All determinations were made in triplicate.  
 
Scanning electron microscopy (SEM) of SLNs 
 
The surface morphology and stability of SLNs 
were studied by SEM (VP-1455, LEO, Germany).  
A drop of the SLN sample was applied evenly on 
the double-adhesive tape mounted on aluminium 
stub and dried at room temperature [9]. The dried 
sample was then sputter-coated by a thin layer of 
platinum under argon atmosphere using a 
sputter-coater (Polaron-England), and then 
examined by SEM. 
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Determination of clindamycin phosphate 
concentration 
 
HPLC determination of the clindamycin 
concentration was performed using an E4320V2 
HPLC system (Knauer, Germany) at 220 nm. A 
Nucleodur® column (5 µm, 250 mm × 4.6 mm, 
Macherey-Nagel, Germany) was used. The 
mobile phase consisted of phosphate buffer 
(pH7): acetonitrile (775:225) at a flow rate of 1.5 
mL/min. An injection volume of 20 µL was used, 
and clindamycin could be detected at a retention 
time of 3.5 min and a wavelength of 220 nm. The 
linear correlation between the peak area and the 
clindamycin concentration (R2 = 0.9899) was 
obtained within the concentration range of 0.01 – 
6 mg/mL, with a limit of quantification of 0.008 
mg/mL. 
 
Determination of drug loading 
 
Following the preparation, the aqueous 
dispersion was centrifuged at 10,000 rpm for 30 
min. The amount of free drug in the supernatant 
was determined by HPLC at 220 nm. The 
amount of loaded drug was calculated by 
subtracting the amount of free drug from the 
initial drug amount. The drug loading efficiency 
(DLE) was calculated as in Eq 1. 
 
DLE (%) = {(Wi – Wf)/Wi}100 ………….. (1) 
 
where Wi is the initial amount drug added in the 
dispersion and Wf the amount of free drug in the 
supernatant. 
 
In vitro drug release studies 
 
The method employed for the release 
investigation was the modified paddle method 
(USP type II apparatus). Phosphate buffer 
solution (30 ml, pH 7) was placed in a modified 
50 mL vessel and equilibrated at 37 ± 0.5 °C. 
SLNs were separated by centrifugation at 10,000 
rpm for 30 min. the SLN sediments were diluted 
with 1 mL distilled water and transferred to 
dissolution vessel..The speed of the rotation of 
the paddle was set at 100 rpm. The dissolution 
medium (0.5 mL) was withdrawn at 0.5, 1, 2, 3, 
4, 8, 12, 24, 48, 72, 96, and 120 h and analyzed 
by HPLC as described previously. A graph of % 




The effects of independent variables on the 
experimental response (drug loading) were 
modeled using a second order polynomial 
equation with a backward, stepwise linear 
regression technique. Only significant terms (p < 
0.05) were chosen for the final model. ANOVA 
and modeling process were performed using 
SPSS for Windows®, Version 16.0 (SPSS Inc., 
USA). The related surface plots were obtained by 
Statgraphics for Windows®, Version 5.1 plus 




Particle size and morphology 
 
The particle size of different formulations and 
their PDI are presented in Table 2. Their particle 
size ranged from 400 – 900 nm for all 
formulations and no clear pattern was observed. 
Furthermore, PDI was < 0.5 for all formulations. 
SEM photographs of clindamycin SLNs showed 
they were semispherical with a size range which 
was consistent with PCS measurements (data 
not shown).  
 
 
Table 2: Particle size, polydispersity index (PDI) and drug loading of SLN formulations 
 
 
SLN-ALG SLN-DS Formulation 
no. Particle size 
(nm) 




PDI Drug loading (%) 
1 38 ± 482 0.34 1.32 ± 4.07 38 ± 482 0.34 1.32 ± 4.07 
2 18 ± 570 0.34 0.40 ± 0.29 18 ± 570 0.34 0.29 ± 0.40 
3 51 ± 457 0.36 0.35 ± 0.13 51 ± 457 0.36 0.35 ± 0.13 
4 28 ± 705 0.31 5.92 ± 0.44 34 ± 705 0.31 5.92 ± 0.44 
5 45 ± 711 0.33 2.99 ± 1.00 18 ± 529 0.31 8.28 ± 1.85 
6 25 ± 714 0.28 6.73 ± 0.49 34 ± 324 0.4 15.27 ± 3.05 
7 32 ± 673 0.36 3.23 ± 0.79 26 ± 576 0.38 14.12 ± 0.15 
8 38 ± 501 0.32 6.49 ± 0.75 53 ± 582 0.35 12.89 ± 1.37 
9 40 ± 883 0.29 2.61 ± 0.89 19 ± 472 0.28 6.76 ± 1.50 
10 33 ± 893 0.38 3.98 ± 1.04 28 ± 275 0.33 13.10 ± 2.45 
11 19 ± 384 0.41 4.15 ± 0.66 31 ± 399 0.33 15.95 ± 0.76 
12 21 ± 439 0.32 5.09 ± 0.84 50 ± 603 0.34 18.19 ± 0.31 
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Fig 1: Effect of different factors on drug loading of dextran sulfate-containing SLNs 
 




Fig 1: Effect of different factors on drug loading of dextran sulfate-containing SLNs 
 
 
Fig. 2: Effect of the amounts of drug and surfactants 
on the drug loading of sodium alginate-containing 
SLNs 
 
Drug loading efficiency (DLE) 
 
Table 2 presents the drug loading of SLN 
formulations prepared using dextran sulfate and 
sodium alginate as the polymers and those 
prepared without a polymer. Analysis of the 
effect of variables and their interactions on 
response gave the mathematical models shown 
in Eqs 2 and 3. 
 
  R2=0.921     
 (2)  
   R2=0.528 (3) 
     
Clearly, three variables, viz, amounts of polymer, 
drug, and surfactant, were influential in the 
formulations containing dextran sulfate (Fig 1). 
To maximize drug loading, all three variables 
must be included at their highest levels, and the 
results revealed that the amount of drug had a 
greater effect on loading than the amount of 
surfactants. Moreover, the loading of 
formulations containing sodium alginate was not 
affected by the amount of polymer, whereas the 
amounts of drug and surfactant affected the 
loading (Fig 2). The highest loading was obtained 
when the amounts of drug and surfactant were 
maximal. Formulations F12 containing dextran 
sulfate and F6 containing sodium alginate 
displayed a maximum loading of 18.19 ± 0.31 
and 6.73 ± 0.49 %, respectively. These two 
formulations were used for drug release studies.  
 
Drug release from SLNs 
 
The in vitro drug release profiles of the selected 
SLN formulations consisted of an initial burst 
release followed by a sustained and slow release 
(Fig 3). 
 
Fig 3: Profile of drug release from: (♦) formulation 12 
(dextran sulfate) and (◊) formulaton 6 (Sodium 
alginate) 
 
For F12.DS, 13.46 % of the drug was released in 
the first 2 h, which was considered the burst 
release phase. By 120 h, 38.01 ± 1.48% of the 
drug had been released. Conversely, F6.ALG 
displayed a burst release of 14.26 % of the drug, 
and a maximum of 81.33 ± 2.18 % of the drug 




Particle size and distribution are considered 
important issues when formulating dispersed 
systems, particularly those intended for 
parenteral or ocular administration. The 
submicron-sized particles and solid state of 
physiological lipid carriers favor the 
pharmaceutical and biopharmaceutical 
applications of SLNs [8]. Nanoparticles have 
adhesive properties that could prolong the 
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residence time of the drug in the administered 
area and increase its bioavailability. 
 
In this study, particle size was not influenced by 
the polymer type or the amount of drug, polymer, 
or surfactant. However, in a previous study on 
the development of SLNs containing ionically 
complexed chemotherapeutic drugs, particle size 
appeared to be increased by the addition of the 
amount of polymer and drug [10]. This may be 
attributed to the additional cold-homogenization 
stage in the preparation method which can help 
to achieve partly uniform and narrow particle size 
distribution. The loading results were studied 
using a factorial design for the formulations 
separately prepared with dextran sulfate or 
sodium alginate. The results of the present study 
revealed that the presence of the polymer 
enhances the loading of hydrophilic drugs and 
that the type of polymer has a considerable effect 
on the amount of loading. In general, SLNs 
prepared with dextran sulfate as the polymer had 
a higher degree of loading than those made with 
sodium alginate. The ionic complex created 
between the polymers and clindamycin is 
necessary for the establishment of polymer 
hybrid SLNs. The complex between clindamycin 
and dextran sulfate or sodium alginate can be 
affected by the branching density, chain length, 
and degree of substitution [10]. It has been found 
that the encapsulation of cationic chemothe-
rapeutics could be enhanced using dextran 
sulfate as an anionic polymer [10]. Dextran 
sulfate has a high degree of sulfate replacement, 
and the high density of dextran sulfate allows it to 
connect with cationic drugs, which results in 
higher drug loading in SLNs. In addition, the low 
molecular weight of dextran sulfate and the low 
density of its branches (<5%) make it highly 
soluble in water, and thus, the complex between 
clindamycin and dextran sulfate is more 
complete [10]. 
 
The SLNs in the present investigation had a 
short period of burst release followed by a 
sustained and slow release, which is common in 
hydrophilic drug-containing SLNs [14,15]. In 
many cases, the burst release is due to the 
hydrophilic drugs accumulated at the o/w 
interface and in the outer shell during SLN 
preparation [16]. The prolonged release was due 
to the drug incorporated in the core. The ionic 
polymer can facilitate drug partitioning in the lipid 
phase, which can result in slower drug release. 
For example, increasing the amount of dextran 
sulfate in the formulations can reduce the initial 
burst release and slow the long-term release 




Incorporation of anionic polymers can increase 
the loading of clindamycin phosphate into SLNs 
by decreasing the hydrophilicity of the drug. 
Dextran sulfate has significant effect on drug 
loading and a greater impact on prolonging drug 
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